Development built on strong IL-7R biological rationale
• Chronic Pouchitis offers a capital-efficient rare-disease path with fast route to market
• Hidradenitis Suppurativa enables rapid proof-of-concept in a large dermatology market
• First Phase 2 clinical trial expected to start in H2 2026, subject to financing
• Ulcerative Colitis remains a key indication to be partnered
Nantes, France, January 29, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173;
Mnemo: OSE), today announced the selection of two new clinical indications for lusvertikimab (OSE-127):
chronic pouchitis and hidradenitis suppurativa (HS). These indications were chosen based on strong, IL-7R-
driven biology and are fully aligned with the Company’s 2026–2028 strategic plan to expand lusvertikimab
into targeted, high value immune-mediated diseases. Development of one or both indications will proceed
subject to financing, with the first Phase 2 clinical trial planned to initiate in H2 2026